Bard wins patent infringement suit against Boston Scientific.MURRAY HILL, NJ--(BUSINESS WIRE)--June 24, 1997--A federal court jury has awarded C. R. Bard C. R. Bard, Inc. (NYSE: BCR) is one of the large S&P 500 companies of the United States, a surgical specialties and hospital medical device manufacturer in Murray Hill, New Jersey. It is named after its founder, who sold the company within only a few years of its founding. , Inc. (NYSE-BCR) damages of $10.8 million in a patent infringement patent infringement n. the manufacture and/or use of an invention or improvement for which someone else owns a patent issued by the government, without obtaining permission of the owner of the patent by contract, license or waiver. suit by Bard against Boston Scientific Corporation. The jury determined that an esophageal dilatation catheter sold by Boston Scientific's Microvasive Endoscopy endoscopy Examination of the body's interior through an instrument inserted into a natural opening or an incision, usually as an outpatient procedure. Endoscopes include the upper gastrointestinal endoscope (for the esophagus, stomach, and duodenum), the colonoscope (for the Division infringed a United States patent issued to Bard. Esophageal dilatation catheters are used to treat strictures of the esophagus resulting from acid reflux acid reflux n. See heartburn. disease, esophageal cancer and other causes. Bard is a leading supplier of these devices worldwide. Because the infringement had affected sales of Bard's Eliminator(TM) dilatation catheter, the jury compensated Bard with an award of lost profits, as well as other damages, for a total award of $10.8 million. William H. Longfield, chairman and chief executive officer commented, "We are pleased that the jury agreed with us and awarded appropriate compensation for our losses. Bard will continue to vigorously protect its intellectual property." C. R. Bard, Inc., headquartered in Murray Hill, New Jersey
CONTACT: E. L. Parker C. R. Bard, Inc. (908) 277-8059 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion